The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Myasthenia Gravis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market.
Some of the key takeaways from the Myasthenia Gravis Pipeline Report:
Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years.
Myasthenia Gravis companies working in the treatment market are Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others, are developing therapies for the Myasthenia Gravis treatment
Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others are expected to have a significant impact on the Myasthenia Gravis market in the coming years.
In December 2024, Cartesian Therapeutics has released updated efficacy and safety findings from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The results showed sustained responses at the 12-month mark. The trial (NCT06038474) was a double-blind, placebo-controlled, crossover study conducted in an open-label format, involving 36 severely symptomatic, heavily pre-treated patients. Half of the participants received a placebo, while the other half were treated with Descartes-08. Both groups underwent six weekly outpatient infusions without the need for preconditioning chemotherapy.
In December 2024, Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced the initiation of enrollment for the Ntrust-2 trial and the IND clearance for an investigator-sponsored trial (IST) of NKX019. NKX019 is Nkarta’s allogeneic, CD19-directed CAR NK-cell therapy, which will be evaluated in patients with myasthenia gravis (MG). The multi-center Ntrust-2 trial will assess NKX019 across three cohorts, including systemic sclerosis (SSc/scleroderma), idiopathic inflammatory myopathy (IIM/myositis), and ANCA-associated vasculitis (AAV). The IST will be conducted by researchers at the University of California, Irvine, and the University of Kansas Medical Center.
In August 2024, Merck KGaA (Merck) administered the first dose in a Phase III clinical trial evaluating oral Cladribine for the treatment of generalized myasthenia gravis (gMG), a rare neuromuscular condition. Named MyClad, this global, randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Cladribine capsules in comparison to a placebo.
In June 2024, Johnson & Johnson (NYSE: JNJ) announced positive results from the Phase 3 Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis (gMG). Patients receiving nipocalimab alongside standard care (SOC) showed superior improvement over those receiving placebo plus SOC, as measured by the primary endpoint of the MG-ADL score improvement from baseline over 24 weeks. These findings are part of a presentation and one of eight abstracts Johnson & Johnson will present at the European Academy of Neurology (EAN) 2024 Congress and will be included in regulatory submissions later this year.
In January 2024, Cartesian Therapeutics’ Descartes-08, an investigational autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune diseases like myasthenia gravis (MG), has shown clinically significant improvements in the phase 2a part of a clinical trial (NCT04146051) for MG. All 7 patients in the phase 2a portion, treated with a single infusion of Descartes-08 weekly for 6 weeks, demonstrated substantial and lasting clinical improvements in MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised assessments at 9 months post-treatment.
In January 2024, RYSTIGGO® (rozanolixizumab-noli) is a specialized treatment for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Created by the Belgian biopharmaceutical company UCB, RYSTIGGO is provided in a single-dose vial containing 280mg/2ml (140mg/ml) of a colorless to light brownish-yellow solution, intended for subcutaneous injection.
Myasthenia Gravis Overview
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to “grave muscle weakness,” reflects the primary symptom of the condition. MG occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles.
Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight
Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include:
Povetacicept: Alpine Immune Science
TOL 2: Toleranzia
MuSK-CAART: Cabaletta Bio
RLYB116: Rallybio
ALXN2050: Alexion Pharmaceuticals
TAK-079: Takeda
Descartes-08: Cartesian Therapeutics
Telitacicept: RemeGen
Inebilizumab: Horizon Therapeutics
Myasthenia Gravis Route of Administration
Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical
Molecule Type
Myasthenia Gravis Molecule Type
Myasthenia Gravis Products have been categorized under various Molecule types, such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type
Myasthenia Gravis Pipeline Therapeutics Assessment
Myasthenia Gravis Assessment by Product Type
Myasthenia Gravis By Stage and Product Type
Myasthenia Gravis Assessment by Route of Administration
Myasthenia Gravis By Stage and Route of Administration
Myasthenia Gravis Assessment by Molecule Type
Myasthenia Gravis by Stage and Molecule Type
DelveInsight’s Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the emerging Myasthenia Gravis therapies
Some of the key companies in the Myasthenia Gravis Therapeutics Market include:
Key companies developing therapies for Myasthenia Gravis are – CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others.
Myasthenia Gravis Pipeline Analysis:
The Myasthenia Gravis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.
Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myasthenia Gravis drugs and therapies
Myasthenia Gravis Pipeline Market Drivers
Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market.
Myasthenia Gravis Pipeline Market Barriers
However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth.
Scope of Myasthenia Gravis Pipeline Drug Insight
Coverage: Global
Key Myasthenia Gravis Companies: Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others
Key Myasthenia Gravis Therapies: Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others
Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies
Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers
Request for Sample PDF Report for Myasthenia Gravis Pipeline Assessment and clinical trials
Table of Contents
1. Myasthenia Gravis Report Introduction
2. Myasthenia Gravis Executive Summary
3. Myasthenia Gravis Overview
4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment
5. Myasthenia Gravis Pipeline Therapeutics
6. Myasthenia Gravis Late Stage Products (Phase II/III)
7. Myasthenia Gravis Mid Stage Products (Phase II)
8. Myasthenia Gravis Early Stage Products (Phase I)
9. Myasthenia Gravis Preclinical Stage Products
10. Myasthenia Gravis Therapeutics Assessment
11. Myasthenia Gravis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myasthenia Gravis Key Companies
14. Myasthenia Gravis Key Products
15. Myasthenia Gravis Unmet Needs
16 . Myasthenia Gravis Market Drivers and Barriers
17. Myasthenia Gravis Future Perspectives and Conclusion
18. Myasthenia Gravis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
